|
|
K6H6/B5
|
|
|
R Levy
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension
|
|
|
human (B cell lymphoma); mouse (myeloma)
|
|
|
lymphoblast
|
|
|
Organ: lymph node
Disease: nodular lymphoma
Cell Type: hybridoma: B lymphocyte; somatic cell hybrid
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
The line was produced from a fusion of P3/NSI/1-Ag4-1 cells with malignant cells from a human nodular lymphoma.
The cells are deficient in hypoxanthine phosphoribosyltransferase (HPRT) and are excellent fusion partners for human B cells.
Originally the cells secreted human IgM with a lambda light chain; however, with continuous passage they spontaneously lost the ability to secrete immunoglobulin.
Tested and found negative for ectromelia virus (mousepox).
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
|
|
|
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) cells/ml and maintain between 1 X 10(5) and 1 X 10(6) cells/ml.
Medium Renewal: Every 2 to 3 days
|
|
|
Freeze medium: complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
|
|
|
Recommended medium (without the additional serum described under ATCC Medium): ATCC 30-2001
Recommended serum: ATCC 30-2020
Cell culture tested DMSO: ATCC 4-X
Erythrosin B vital stain solution: ATCC 30-2404
|
|
|
1625: Carroll WL, et al. Mouse X human heterohybridomas as fusion partners with human B cell tumors. J. Immunol. Methods 89: 61-72, 1986. PubMed: 3084658
|
